Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis
Joshua M Uronis, Janelle C Arthur, Temitope Keku, Anthony Fodor, Ian M Carroll, Myrella L Cruz, Caroline B Appleyard, Christian Jobin, Joshua M Uronis, Janelle C Arthur, Temitope Keku, Anthony Fodor, Ian M Carroll, Myrella L Cruz, Caroline B Appleyard, Christian Jobin
Abstract
Background: Compositional changes within the normal intestinal microbiota have been associated with the development of various intestinal inflammatory disorders such as pouchitis and inflammatory bowel diseases (IBD). Therefore, it has been speculated that manipulation of a dysbiotic intestinal microbiota has the potential to restore microbial homeostasis and attenuate inflammation.
Methods: We performed community composition analyses by terminal restriction fragment length polymorphism (T-RFLP) of the bacterial 16S ribosomal RNA gene to investigate the impact of the probiotic VSL#3 on colonic microbial community composition and development of trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats.
Results: TNBS-induced chronic colitis was significantly reduced in VSL#3-fed rats compared to controls (P < 0.05). T-RFLP analysis revealed distinct microbial communities at luminal versus mucosal sites. Within the luminal microbiota, chronic colitis was associated with an overall decrease in bacterial richness and diversity (Margalef's richness, P < 0.01; Shannon diversity, P < 0.01). This decrease in luminal microbial diversity was enhanced in TNBS-treated rats fed VSL#3 (Margalef's richness, P < 0.001; Shannon diversity, P < 0.001) and significantly correlated with reduced clinical colitis scores (Pearson correlation P < 0.05).
Conclusions: Our data demonstrate that the probiotic VSL#3 alters the composition of the intestinal microbiota and these changes correlate with VSL#3-induced disease protection.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2953593/bin/nihms207629f1.jpg)
Figure 2
VSL#3 administration decreases the biodiversity…
Figure 2
VSL#3 administration decreases the biodiversity of the luminal microbiota. A. Measures of microbial…
Figure 3
VSL#3 does not affect the…
Figure 3
VSL#3 does not affect the biodiversity or species distribution of the mucosally-adherent microbiota.…
Figure 4
Distinct microbial community communities reside…
Figure 4
Distinct microbial community communities reside in the colonic lumen and mucosal tissue. A.…
Figure 5
Clinical score of VSL#3-fed rats…
Figure 5
Clinical score of VSL#3-fed rats correlates with luminal species richness and biodiversity. Luminal…
- Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer.Appleyard CB, Cruz ML, Isidro AA, Arthur JC, Jobin C, De Simone C. Appleyard CB, et al. Am J Physiol Gastrointest Liver Physiol. 2011 Dec;301(6):G1004-13. doi: 10.1152/ajpgi.00167.2011. Epub 2011 Sep 8. Am J Physiol Gastrointest Liver Physiol. 2011. PMID: 21903764 Free PMC article.
- Bifidobacterium longum and VSL#3® amelioration of TNBS-induced colitis associated with reduced HMGB1 and epithelial barrier impairment.Chen X, Fu Y, Wang L, Qian W, Zheng F, Hou X. Chen X, et al. Dev Comp Immunol. 2019 Mar;92:77-86. doi: 10.1016/j.dci.2018.09.006. Epub 2018 Sep 15. Dev Comp Immunol. 2019. PMID: 30227219
- The Probiotic VSL#3 Modulates Colonic Macrophages, Inflammation, and Microflora in Acute Trinitrobenzene Sulfonic Acid Colitis.Isidro RA, Lopez A, Cruz ML, Gonzalez Torres MI, Chompre G, Isidro AA, Appleyard CB. Isidro RA, et al. J Histochem Cytochem. 2017 Aug;65(8):445-461. doi: 10.1369/0022155417718542. Epub 2017 Jul 10. J Histochem Cytochem. 2017. PMID: 28692320 Free PMC article.
- Gene expression profiling identifies mechanisms of protection to recurrent trinitrobenzene sulfonic acid colitis mediated by probiotics.Mariman R, Kremer B, van Erk M, Lagerweij T, Koning F, Nagelkerken L. Mariman R, et al. Inflamm Bowel Dis. 2012 Aug;18(8):1424-33. doi: 10.1002/ibd.22849. Epub 2011 Dec 11. Inflamm Bowel Dis. 2012. PMID: 22162025
- Participation of the intestinal microbiota in the mechanism of beneficial effect of treatment with synbiotic Syngut on experimental colitis under stress conditions.Konturek PC, Konturek K, Brzozowski T, Wojcik D, Magierowski M, Targosz A, Krzysiek-Maczka G, Sliwowski Z, Strzalka M, Magierowska K, Szczyrk U, Kwiecien S, Ptak-Belowska A, Neurath M, Dieterich W, Wirtz S, Zopf Y. Konturek PC, et al. J Physiol Pharmacol. 2020 Jun;71(3). doi: 10.26402/jpp.2020.3.03. Epub 2020 Sep 26. J Physiol Pharmacol. 2020. PMID: 32991312
- Inflammatory Bowel Diseases and Gut Microbiota.Haneishi Y, Furuya Y, Hasegawa M, Picarelli A, Rossi M, Miyamoto J. Haneishi Y, et al. Int J Mol Sci. 2023 Feb 14;24(4):3817. doi: 10.3390/ijms24043817. Int J Mol Sci. 2023. PMID: 36835245 Free PMC article. Review.
- Evolutionary Insights Into Microbiota Transplantation in Inflammatory Bowel Disease.Wang X, Zhao J, Feng Y, Feng Z, Ye Y, Liu L, Kang G, Cao X. Wang X, et al. Front Cell Infect Microbiol. 2022 Jun 22;12:916543. doi: 10.3389/fcimb.2022.916543. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35811664 Free PMC article. Review.
- The Effects of Single Strains and Mixtures of Probiotic Bacteria on Immune Profile in Liver, Spleen, and Peripheral Blood.Fong FLY, El-Nezami H, Mykkänen O, Kirjavainen PV. Fong FLY, et al. Front Nutr. 2022 Apr 12;9:773298. doi: 10.3389/fnut.2022.773298. eCollection 2022. Front Nutr. 2022. PMID: 35495948 Free PMC article.
- Health improvements of type 2 diabetic patients through diet and diet plus fecal microbiota transplantation.Su L, Hong Z, Zhou T, Jian Y, Xu M, Zhang X, Zhu X, Wang J. Su L, et al. Sci Rep. 2022 Jan 21;12(1):1152. doi: 10.1038/s41598-022-05127-9. Sci Rep. 2022. PMID: 35064189 Free PMC article. Clinical Trial.
- Characteristics of an In Vitro Mesenteric Lymph Node Cell Suspension Model and Its Possible Association with In Vivo Functional Evaluation.Feng S, Li J, Qu D, Tian F, Yu L, Zhang H, Chen W, Zhao J, Zhai Q. Feng S, et al. Int J Mol Sci. 2022 Jan 17;23(2):1003. doi: 10.3390/ijms23021003. Int J Mol Sci. 2022. PMID: 35055188 Free PMC article.
- Research Support, N.I.H., Extramural
- Animals
- Colitis / chemically induced
- Colitis / microbiology*
- Colitis / therapy*
- Male
- Metagenome*
- Probiotics / therapeutic use*
- Rats
- Rats, Sprague-Dawley
- Trinitrobenzenesulfonic Acid / toxicity*
- Trinitrobenzenesulfonic Acid
- Full Text Sources
- Other Literature Sources
- Medical
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2953593/bin/nihms207629f2.jpg)
Figure 3
VSL#3 does not affect the…
Figure 3
VSL#3 does not affect the biodiversity or species distribution of the mucosally-adherent microbiota.…
Figure 4
Distinct microbial community communities reside…
Figure 4
Distinct microbial community communities reside in the colonic lumen and mucosal tissue. A.…
Figure 5
Clinical score of VSL#3-fed rats…
Figure 5
Clinical score of VSL#3-fed rats correlates with luminal species richness and biodiversity. Luminal…
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2953593/bin/nihms207629f3.jpg)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2953593/bin/nihms207629f4.jpg)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2953593/bin/nihms207629f5.jpg)
Source: PubMed